Molecular Response LLC Company Profile

05:18 EDT 15th August 2018 | BioPortfolio

Molecular Response is a leader in advancing targeted therapeutics through intelligently designed, clinically validated companion diagnostics. Our goal is to reduce risk and cost of therapeutic drug development for our partners by translating clinically relevant molecular response marker data into high-value knowledge while fully integrated into existing pharmaceutical development processes and programs; Our results reduce risk and cost of drug development and allow for the most informed decisions with best chance of success to advance therapeutic programs.

News Articles [967 Associated News Articles listed on BioPortfolio]

CDMO BioDuro acquires Molecular Response

BioDuro has acquired Molecular Response LLC and its translational oncology research platform, which includes a biobank of more than 100,000 viable tumor specimens.

Molecular response of muscle to different types of exercise identified

Exercise in the future could be customized for individuals based on genomics, according to a new study. For years, scientists have studied the effects of different types of exercise on the human body,...

Study unravels novel cellular and molecular pathway that regulates innate, adaptive immunity

Researchers at Brigham and Women's Hospital have discovered a new cellular and molecular pathway that regulates CD4+ T cell response--a finding that may lead to new ways to treat diseases that result ...

Molecular Partners says 5 of 8 patients responded in multiple myeloma trial

ZURICH (Reuters) - Molecular Partners said on Friday that five of eight patients with advanced multiple myeloma in a Phase II study showed an objective response to a combination therapy that includes ...

Hybrigenics (ALHYG) - Leukaemia pipeline advances with new data

Edison Investment Research - Pharmaceutical & healthcare - Hybrigenics: Hybrigenics has published data from a Phase II study in chronic myeloid leukaemia (CML). After one year of treatment, 40% of pat...

Molecular Templates' NHL candidate shows higher response rates with low baseline Rituxan levels

New Research Provides Expanded Insights into the Brain's Response to Opioids

NewsResearchers have developed a tool that gives deeper insights into the brain's response to opioids. Using mass spectrometry, they determined changes of proteins' phosphorylation patterns - the mole...

Keap1–MCM3 interaction is a potential coordinator of molecular machineries of antioxidant response and genomic DNA replication in metazoa

Drugs and Medications [2 Associated Drugs and Medications listed on BioPortfolio]

Nilandron [sanofi-aventis U.S. LLC]

NILANDRON (nilutamide)Tablets

Salsalate [Libertas Pharma, Inc.]

Salsalate Tablets, USP 500 and 750 mgRx Only

PubMed Articles [2584 Associated PubMed Articles listed on BioPortfolio]

Danger Signals in the ICU.

Sterile and infectious critical illnesses often result in vasoplegic shock and a robust systemic inflammatory response that are similar in presentation. The innate immune system is at the center of th...

Finding Sugar in the Pantry: How Galectins Detect and Signal Lysosomal Damage.

In this issue of Molecular Cell, Jia et al. (2018) identify a lysosomal damage-response pathway centered on galectin 8 and 9 that feeds back on mTORC1 signaling. In response to lysosome-damaging agen...

Pathogen- and Danger-Associated Molecular Patterns and the Cytokine Response in Sepsis.

The sepsis syndrome is a systemic host inflammatory response accompanied by organ dysfunction in response to invading microbial pathogens. The host recognizes both danger and pathogens through its pat...

Comparative analyses of nilotinib versus high-dose imatinib versus sustained standard-dose imatinib in patients with chronic phase chronic myeloid leukemia following suboptimal molecular response to first-line imatinib.

The aim of this study was to investigate the efficacy of nilotinib (NIL) versus high-dose imatinib (IM) versus sustained standard-dose IM for patients with chronic myeloid leukemia (CML) with suboptim...

An Overview of Molecular Profiles in Ulcerative Colitis-Related Cancer.

Ulcerative colitis (UC) is an independent risk factor of colorectal cancer (CRC). Both genetic and epigentic events induce a unique molecular profile during the development from UC to UC-related CRC (...

Clinical Trials [3775 Associated Clinical Trials listed on BioPortfolio]

Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib

This exploratory study will evaluate the change in molecular response in chronic myelogenous leukemia - chronic phase patients with a complete cytogenetic response and have a suboptimal mo...

Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in Cytogenetic Response Without Molecular Response

Imatinib mesylate is standard treatment of Chronic myeloid leukaemia, complete cytogenetic response is obtained in most of cases but molecular response concerned only a small part of the p...

Molecular Processes of the Relaxation Response in Older Adults

The purpose of this study is to examine the molecular (nitric oxide) and biochemical (epinephrine, norepinephrine, cortisol and ACTH) parameters that are associated with RR elicitation and...

Retrospective Study Assessing Molecular Features Predicting Response to Cetuximab

The primary objective is to identify molecular features predicting response or resistance to cetuximab

Molecular Response After Concurrent Exercise With Low Glycogen

This is a randomized, counterbalanced crossover design, in which 14 male subjects will complete two experimental trials. Each trial will be separated by a minimum of at least 12 days (rang...

Companies [1287 Associated Companies listed on BioPortfolio]

Molecular Response LLC

Molecular Response is a leader in advancing targeted therapeutics through intelligently designed, clinically validated companion diagnostics. Our goal is to reduce risk and...

Molecular Response

Molecular Response is a leader in advancing targeted therapeutics through intelligently designed, clinically validated companion diagnostics. Our goal is to reduce risk and increa...

Church & Dwight, Co., Inc.

Church and Dwight, Co., Inc., headquartered in Princeton, NJ, distributes First Response Early Result Pregnancy Test and other First Response products, including First Response Gold Digital, First Res...

Gene Network Sciences, Inc.

Gene Network Sciences ( is a leader in biosimulation with its ability to derive molecular mechanisms of drugs and diseases directly from molecular profiling and clinical dat...

Nova Molecular Incorporated

Nova Molecular Inc. (NMI) is a Montreal based CNS drug discovery company focused on understanding neuronal degeneration, disease progression, repair mechanisms, therapeutic response and development ba...

More Information about "Molecular Response LLC" on BioPortfolio

We have published hundreds of Molecular Response LLC news stories on BioPortfolio along with dozens of Molecular Response LLC Clinical Trials and PubMed Articles about Molecular Response LLC for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Molecular Response LLC Companies in our database. You can also find out about relevant Molecular Response LLC Drugs and Medications on this site too.

Quick Search


Relevant Topics

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Corporate Database Quicklinks

Searches Linking to this Company Record